CD274 and neoplasm: However, blockade of PD-1/PD-L1 pathways using anti-PD-1 Abs, pembrolizumab, and nivolumab produces tumor regression in only a minority of recurrent human papillomavirus (HPV)-positive oropharyngeal cancer patients [15,16,17,18].